IBRX250117C3000
- 0.05
- -0.08-61.54%
ImmunityBio Newsroom
ImmunityBio Analyst Ratings
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target
ImmunityBio Analyst Ratings
ImmunityBio Analyst Ratings
IBRX Soars 47% on Initial Trials For Cell Therapy Product
EF Hutton Initiates ImmunityBio(IBRX.US) With Buy Rating, Announces Target Price $30
EF Hutton Initiates Coverage On ImmunityBio With Buy Rating, Announces Price Target of $30
ImmunityBio Analyst Ratings
Jefferies Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $8
Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), ImmunityBio (IBRX) and Neurocrine (NBIX)
Piper Sandler Maintains ImmunityBio(IBRX.US) With Hold Rating, Cuts Target Price to $4.75
Piper Sandler Keeps Their Hold Rating on ImmunityBio (IBRX)
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Idexx Laboratories (IDXX) and ImmunityBio (IBRX)
ImmunityBio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Healthcare Services (HCSG) and ImmunityBio (IBRX)
ImmunityBio (IBRX) Gets a Hold From Piper Sandler
Analysts Conflicted on These Healthcare Names: Masimo (MASI), ImmunityBio (IBRX) and Madrigal Pharmaceuticals (MDGL)
ImmunityBio Analyst Ratings
Piper Sandler Reaffirms Their Hold Rating on ImmunityBio (IBRX)
ImmunityBio (IBRX) Gets a Buy From Jefferies